Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials
Everyone is talking about the GLP-1 battle between Eli Lilly and Novo Nordisk, but Pfizer wants in on the fight, too.
Pfizer, once an underdog in the pharmaceutical world, is poised to disrupt the obesity drug market with a series of Phase 3 trials. Despite initially withdrawing from GLP-1 drug development, Pfizer has since acquired a promising candidate and is now racing to bring a monthly injection option to market. This convenience factor could give Pfizer's product an edge over the once-weekly or daily injections offered by competitors Novo Nordisk and Eli Lilly.
With a robust pipeline of 10 late-stage trials, Pfizer is well-positioned to capture a significant share of the growing GLP-1 market. Investors may have underestimated Pfizer's potential, as evidenced by the company's 5.5% dividend yield, which outpaces its peers. As a long-term dividend investor, now may be an opportune moment to consider adding Pfizer to your portfolio, particularly as the company edges closer to an approved GLP-1 product.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
